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Big Promise
rom the Very Small
dentification of Circulating Embryonic
tem-Like Pluripotent Cells in Patients
ith Acute Myocardial Infarction*
ouglas W. Losordo, MD, FACC, Raj Kishore, PHD
hicago, Illinois
he available evidence showing improvement in myocardial
unction after transplantation of autologous bone marrow
BM)-derived stem/progenitor cells, both in pre-clinical as
ell as in available clinical trials, remains a potent force
riving discovery and clinical development simultaneously
nd has provided new hope for patients with debilitating
eart diseases. However, certain potential limitations of
utologous BM- or peripheral blood-derived stem/
rogenitor cells have been recently identified. Long-term
ollow up in one study revealed a “catch-up” of placebo-
reated patients, resulting in an decrease in the initially
bserved advantage of BM cell infusion in acute myocardial
nfarction (MI) patients (1). Additionally, risk factors for
See page 1
oronary artery disease are reported to be associated with a
educed number of and impaired functional activity of
ndothelial progenitor cells (EPCs) in the peripheral blood
f patients (2,3). Heterogeneity of BM-derived stem cells,
ncomplete mechanistic insights into their function, limited
lasticity, and trans-differentiation potential to various lin-
ages of cells are also the subject of intense debate. More-
ver, the stability of trans-differentiated cells to maintain
ewly acquired phenotype and the heritability of such
hanges remain to be defined. The inherent plasticity of
mbryonic stem cells (ESCs) is therefore argued to be
onsidered for their potential application in regenerative
edicine. Although ESCs have been used in animal studies
f cardiac repair (4,5), ethical and regulatory issues as well as
mmunogenicity limit the potential therapeutic utility of
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.s
From the Feinberg Cardiovascular Research Institute, Feinberg School of Medi-
ine, Northwestern University, Chicago, Illinois.SCs for cardiac repair in humans. Moreover, successful
eneration of patient-specific ESCs by therapeutic cloning
s yet to be achieved.
Lately, oocyte-independent generation of ESCs, also
ermed as induced pluripotent cells (iPS), by epigenetic
eprogramming of adult somatic cells has generated signif-
cant enthusiasm. These studies, including those from our
aboratories, utilized 3 basic methodologies to generate
SCs from somatic cells: 1) somatic-ESC fusion; 2) retro-
iral transduction of ESC-specific genes; and 3) exposure of
ermeabilized somatic cells to ESC cell-free extracts. The
omatic-ESC fusion (6,7) strategy, although excellent for
echanistic studies, retains certain drawbacks that are
ssociated with oocyte-dependent therapeutic cloning. First,
he 2 cells used to generate hybrid cells are not derived from
n autologous source; second, the efficiency of fusion re-
ains low (1 to 3 in 1,000); third, the genetic stability of
eterokaryon hybrids remains to be established: one will
ave to devise the technological innovations to delete the
dditional set of chromosomes; and finally, the efficacy of
eprogrammed cells to retain the ESC-like properties if the
SC-derived nucleus is removed remains to be elucidated.
ecently, a major breakthrough was reported whereby
orced expression of transcription factors Oct-4, Sox2,
-Myc, and Klf4 were shown to induce pluripotency in
rimary mouse fibroblasts (8) and in human fibroblasts
sing either Oct-4, Sox2, c-myc, and Klf4 combination (9)
r Oct-4, Nanog, Sox2, and lin28 combination (10). Al-
hough these studies did provide the evidence that overex-
ression of these ESC-specific genes leads to the derivation
f embryonic stem-like cells from primary human fibro-
lasts, several critical questions were not answered by these
tudies. First, it seems that the requirement of these factors
r their combination is varied, indicating that some of these
actors may be dispensable. Second, because 4 transcription
actors were transduced by constitutively expressed retroviral
ectors, it is unclear why the cells could be induced to
ifferentiate and whether continuous vector expression was
equired for the maintenance of the pluripotent state.
ecently, we have reported the generation of ESC-like
luripotent cells from NIH3T3 fibroblasts utilizing murine
SC-free extracts. Like the other 2 types of iPS cells
iscussed previously, these cells can differentiate into cells
epresentative of all 3 germ layers and significantly enhance
ost-acute MI cardiac function and myogenesis when trans-
lanted into a mouse acute MI model (11). Despite these
xciting breakthroughs, these iPS cells are not yet ready to
e translated into clinical applications.
The ideal cell type for clinical applications in post-acute
I myocardial repair would therefore be one that is
utologous and yet possesses ESC-like plasticity for differ-
ntiation. In this regard, the study by Wojakowski et al.
12), published in this issue of the Journal, is of considerable
nterest. The investigators report the identification of a
ubset of nonhematopoetic, BM-derived cells that express a
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December 30, 2008/January 6, 2009:10–2 Big Promise of Small Cellsumber of ESC-specific transcripts and that are mobilized
nto peripheral blood in patients after acute MI. These cells,
ermed very small embryonic-like stem cells (VSELs) based
n their size (7 to 8 m), may potentially represent a cell
ype for use in the cardiac repair. They are endogenous,
utologous, unmodified, and pluripotent, thus bridging the
ap between adult and embryonic stem cell phenotypes. The
nvestigators show that VSELs are present in the circulation
f both healthy subjects and patients with acute MI.
nterestingly, acute MI significantly enhances mobilization
f VSELs from the BM to the circulation. Phenotypic
haracterization of these cells confirmed that these cells
xpress markers of pluripotency including Oct-4 and Nanog
s well as cardiomyocyte and endothelial lineage-specific
ranscripts. The current report thus builds on the extensive
unctional and phenotypic characterization of murine
SELs reported in several articles by the same group of
nvestigators (13–17). The VSELs were reported by Kucia
t al. (13) as a rare population of cells in the mouse BM that
ere positive for Sca-1 and negative for both hematopoetic
ineage marker (Lin) and the pan-leukocyte marker CD45
Sca-1/Lin/CD45). Like human VSELs identified in
he current report, these cells expressed a number of
luripotency-associated markers (Oct-4, Nanog, SSEA-1,
ex1) and differentiated in vitro into components of all 3
erm layers. In addition to expressing ESC-specific tran-
cripts, these cells were reported to coexpress markers of
euronal, pancreatic, endothelial, and cardiac lineages (13–
7) and acquired cardiomyocyte phenotype in vitro.
ollow-up studies reported that on experimental acute MI
n mice, these cells are mobilized from the BM (16), and
hen transplanted in murine models of acute MI, these cells
mproved global and regional LV function and showed
vidence of myogenesis and vasculogenesis (17). The human
SELs reported in the present study were not characterized
or their functional or differentiation properties, although
henotypic characterization of these cells led the investiga-
ors to predict similar functional properties as observed for
ouse VSELs. Taken together, these observations in mice
nd in humans confirm the presence of a subset of BM stem
ells that is distinct from the other defined populations and
hat possesses a greater differential potential for cardiac
epair.
Although these observations are exciting and these cells
ay hold promise for regenerative medicine in general and
ardiac regeneration in particular, it is not surprising that a
ovel discovery such as this also raises many questions that
eed to be approached as clinical application is considered.
central scientific question pertains to the origin of these
ells, that is, whether these Oct-4 cells are functional in
teady-state conditions or represent a population of dormant
ells residing in BM/tissue as leftover remnants from
evelopmental embryogenesis. Second, do these cells rep-
esent true embryonic cell behavior and potential, because as
eported by the authors previously, these cells show a certain
egree of lineage commitment (e.g., neural, cardiac, andndothelial). Third, does the pluripotent phenotype ob-
erved for these cells represent steady-state function, or does
t represent an epigenetic phenomenon induced by physio-
ogical stimuli such as myocardial ischemia? In this regard,
ne interesting observation made in the current article is
orth noting. The investigators observed that cells isolated
rom acute MI patients 12 h after MI show a certain level of
ct-4 transcript. However, cells isolated from patients 5
ays after MI showed many-fold higher expression of Oct-4
essenger ribonucleic acid. These data would indicate that
here is a continuous transcription of Oct-4 likely induced
y the signals originating from infracted myocardium. It
ould be interesting to know whether these signals include
ctivation of epigenetic modifiers such as histone deacety-
ases and methylases leading to chromatin modifications and
nhanced transcriptional activation of ESC-specific mark-
rs. A potential limitation of the VSELs is their rarity.
ither refinement of methods to isolate larger numbers of
SELs or ways to expand them ex vivo may be required for
linical applications. Finally, as reported by Wojakowski et
l. (12), the VSELs, despite being phenotypically reminis-
ent of ESCs, suffer similar drawbacks that are noted for
ther adult BM-derived stem cell populations: the number
f these cells diminish with age and with other risk factors
f heart disease (e.g., diabetes). Because the incidence of
eart disease coincides with risk factors, this issue will be the
ubject of ongoing study as these cells are considered for
linical applications. Additionally, limitations associated
ith ESC therapy such as teratoma and tumor formation
lso need to be examined carefully for the VSELs.
Despite these questions, which we believe will be an-
wered in the near future, the identification of this distinct
opulation of autologous ESC-like pluripotent cells seems
uite promising. The VSELs could potentially provide a
eal therapeutic alternative to the ethically controversial and
echnically challenging oocyte-dependent therapeutic clon-
ng and generation of individualized human ESCs. Future
tudy of VSEL cells will provide additional clues regarding
he transcriptional programs that drive pluripotency and
ifferentiation, moving our understanding of basic mecha-
isms forward and tissue regeneration closer to clinical
eality. Until then, it is safe to assume that these small cells
old a big promise for cardiac repair and for other applica-
ions in regenerative medicine.
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